Continuation of androgen deprivation therapy for an additional 24 months improves all disease end points during 15 years of follow-up compared with short-term androgen deprivation in men with locally ...

For the first time ever, NTNU researchers have identified new characteristics of aggressive prostate cancer. The research lays a foundation for the possibility that aggressive prostate cancer can ...

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor growth and slow symptom advance. File Photo by Billie Jean Shaw/UPI A new ...

As we gear up to observe World Cancer Day 2026 under the theme 'United by Unique', let's take a look at the stages of ...

A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...

By KATRINA BRANDON DONATIONS have opened up opportunities at Latrobe Regional Hospital (LRH) thanks to Latrobe's Biggest Ever ...

Add Yahoo as a preferred source to see more of our stories on Google. Joe Biden's Cancer Moonshot initiative had funded hundreds of cancer research projects across the country. AP Photo/Gerald Herbert ...

*Localized: T 1/2, NX or N0, and M0. ‡ Locally advanced: T3/4, NX or N0, and M0, or N1 and M0. ITT: Intention to treat; PSA: Prostate-specific antigen. Reproduced ...

Prostate cancer is the most common cancer among men after skin cancer. Age is a significant risk factor for prostate cancer. Family history and genetic factors play a significant role in prostate ...